ClinicalTrials.gg
Not yet recruitingNCT04850417BA-SCADUpdated Apr 20, 2021

Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection

A Phase 4 interventional study of Beta blocker, aspirin, clopidogrel in Spontaneous Coronary Artery Dissection, sponsored by Spanish Society of Cardiology. Not yet recruiting. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-04-20.

Sponsored by Spanish Society of Cardiology · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Spontaneous coronary artery dissection (SCAD) is a cause of acute coronary syndrome (ACS). Most patients are treated with beta-blockers (BB) and antiplatelet drugs (AP) on empiric basis. The Beta-Blockers and Antiplatelet Agents in Patients with Spontaneous Coronary Artery Dissection (BA-SCAD) randomized clinical trial is an academic, pragmatic, nation-wide, prospective study developed under the auspices of the Spanish Society of Cardiology (SEC) that aims to assess the efficacy of medical therapy in SCAD patients. Using a factorial 2x2 design, patients will be randomized (1:1/1:1) to: 1) BB (yes/no) and 2) short AP regimen (1 month) vs prolonged dual AP therapy (DAPT) (12 months).Only patients with preserved left ventricular ejection fraction (LVEF) will be randomized to BB (yes/no) because patients with LVEF \<40% will receive BB according to current guidelines. Likewise, only medically managed patients will be randomized to short AP therapy vs 1-year DAPT. The study will have a pragmatic, open label, blind outcomes design (PROBE). A total of 600 SCAD patients will be randomized within 2 years (300 per arm in a factorial 2x2 design). The primary efficacy endpoint will include the composite of death, acute myocardial infarction (MI), stroke, coronary revascularization, recurrent SCAD, and unplanned hospitalization for ACS or heart failure at 1 year. The primary safety endpoint will be bleeding. All patients will be clinically followed yearly. The main study will be pragmatic but a comprehensive set of additional studies (clinical, imaging, biomarkers, inflammatory, immunologic, pharmacogenetic and genetic) will be organized to ensure an holistic view on this challenging condition.

Read the detailed description

Spontaneous coronary artery dissection (SCAD) is a relatively rare but important and increasingly recognized cause of acute coronary syndrome (ACS). Most patients presenting with SCAD are treated with beta-blockers (BB) and antiplatelet drugs (AP). Although appealing from a pathophysiological standpoint, such management strategy is completely empiric. The Beta-Blockers and Antiplatelet Agents in Patients with Spontaneous Coronary Artery Dissection (BA-SCAD) randomized clinical trial is an academic, pragmatic, nation-wide, prospective study developed under the auspices of the Spanish Society of Cardiology (SEC) that aims to assess the efficacy of medical therapy in SCAD patients. Using a factorial 2x2 design, patients will be randomized (1:1/1:1) to: 1) BB (yes/no) and 2) short AP regimen (1 month) vs prolonged dual AP therapy (DAPT) (12 months). A conservative medical management will be initially recommended, with coronary revascularization reserved for patients with ongoing/refractory ischemia. Only patients with preserved left ventricular ejection fraction (LVEF) will be randomized to BB (yes/no) because patients with LVEF \<40% will receive BB according to current guidelines. Likewise, only medically managed patients will be randomized to short AP therapy vs 1-year DAPT, because patients requiring coronary interventions will receive DAPT. The study will have a pragmatic, open label, blind outcomes design (PROBE). The type and dose of BB and AP agents will be at the discretion of the treating physician. Treatment adherence will be reinforced and closely monitored and the potential influence of drug discontinuation/cross-over on outcomes will be carefully evaluated. A total of 600 SCAD patients will be randomized within 2 years (300 per arm in a factorial 2x2 design). The primary efficacy endpoint will include the composite of death, acute myocardial infarction (MI), stroke, coronary revascularization, recurrent SCAD, and unplanned hospital admission for ACS or heart failure at 1 year. The primary safety endpoint will be bleeding according the Bleeding Academic Research Consortium (BARC) criteria ≥ 3. An analysis of net clinical benefit, including primary efficacy and safety endpoints, will also be performed. All patients will be clinically followed at 1 year (primary endpoint) and yearly thereafter. Although the main study will be pragmatic, following routine clinical practice, a systematic and comprehensive set of additional ancillary studies and investigations (clinical, imaging, biomarkers, inflammatory, immunologic, pharmacogenetic and genetic) will be prospectively organized to ensure a multidisciplinary and holistic view on this challenging condition.

02

Conditions studied

  • Spontaneous Coronary Artery Dissection

Keywords

  • Spontaneous coronary artery dissection
  • Beta-blockers
  • Antiplatelets
  • Coronary angiography
  • Intracoronary imaging
  • Biomarkers
  • Myocardial infarction
03

In context

Coronary Artery Dissection, Spontaneous

28 studies on the registry are indexed under Coronary Artery Dissection, Spontaneous; 18 are open to participants now.

Browse Coronary Artery Dissection, Spontaneous studies →

Lead sponsor

Spanish Society of Cardiology is the lead sponsor of 23 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Angiographic diagnosis of SCAD
  • Admission for ACS or other manifestations of ischemia

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock or severe hemoynamic instability
  • Concomitant severe heart disease requiring surgical correction (in \<2 years)
  • Medical condition seriously limiting (\< 2 years)
  • Allergies or to drugs required in one of the study arms; the patient may be randomized in the other arm (factorial design)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Beta-blockers and Short Antiplatelet Therapy

    Beta-blockers (experimental) and Short Antiplatelet Therapy (experimental). Aspirin alone recommended for Short Antiplatelet Therapy (The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)

    Drug: Beta blocker, aspirin, clopidogrel

  • Experimental
    Beta-blockers and Long Antiplatelet Therapy

    Beta-blockers (experimental) and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy (The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)

    Drug: Beta blocker, aspirin, clopidogrel

  • Experimental
    No Beta-blockers and Short Antiplatelet Therapy

    No Beta-blockers and Short Antiplatelet Therapy (experimental). Aspirin alone recommended in Short Antiplatelet Therapy (The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)

    Drug: Beta blocker, aspirin, clopidogrel

  • Active comparator
    No Beta-blockers and Long Antiplatelet Therapy

    No Beta-blockers and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy (The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)

    Drug: Beta blocker, aspirin, clopidogrel

Interventions

  • DrugBeta blocker, aspirin, clopidogrel

    Drug pages: Beta blockersStudies of Beta blockersBeta blockers pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClopidogrelStudies of ClopidogrelClopidogrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy

    Also known as: Beta-blockers, Aspirin, Clopidogrel

06

What researchers measure

Primary outcomes

  1. MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes)

    MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes)

    Time frame: 1 year

Secondary outcomes

  1. MACE (death, myocardial infarction, coronary revascularization, stroke and heart failure)

    MACE (death, myocardial infarction, coronary revascularization, stroke and heart failure)

    Time frame: 1, 2 and 3 years

  2. MACE (death, myocardial infarction, coronary revascularization)

    MACE (death, myocardial infarction, coronary revascularization)

    Time frame: 1, 2 and 3 years

  3. MACE (death, myocardial infarction)

    MACE (death, myocardial infarction)

    Time frame: 1, 2 and 3 years

  4. MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes)

    MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes)

    Time frame: 2, 3,4 and 5 years

  5. Safety: Major Bleeding

    Major Bleeding (BARC \>=3)

    Time frame: 1 year

  6. Safety: Bleeding

    Bleeding (BARC \>=2)

    Time frame: 1 year

  7. MACE and Bleeding

    MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes) and bleeding

    Time frame: 1, 2 and 3 years

  8. Death

    Death

    Time frame: 1, 2 and 3 years

  9. Myocardial infarction

    Myocardial infarction

    Time frame: 1, 2 and 3 years

  10. Coronary revascularization

    Coronary revascularization

    Time frame: 1, 2 and 3 years

  11. Recurrent SCAD

    Recurrent SCAD

    Time frame: 1, 2 and 3 years

  12. Stroke

    Stroke

    Time frame: 1, 2 and 3 years

  13. Unplanned admission for heart failure

    Unplanned admission for heart failure

    Time frame: 1, 2 and 3 years

  14. Unplanned admission for acute coronary syndrome with dynamic ECG changes

    Unplanned admission for acute coronary syndrome with dynamic ECG changes

    Time frame: 1, 2, 3 years

Other outcomes

  1. Substudy on strategies and results of coronary interventions

    Strategies and results of coronary interventions (different devices and modalities). Procedural success and angiographic results

    Time frame: Through study completion, up to 5 years

  2. Substudy on angiographic findings in relation to prognosis

    Angiographic analysis (visual and QCA, central corelab). Quantitative coronary angiography analyses (MLD, % diameter stenosis, TIMI Flow)

    Time frame: Through study completion, up to 5 years

  3. Substudy on value of intracoronary imaging in SCAD (OCT and IVUS)

    Intracoronary imaging in SCAD (central corelab) (OCT \[optical coherence tomography\] and IVUS \[intravascular ultrasound\] ). Minimal lumen area.

    Time frame: Through study completion, up to 5 years

  4. Non-invasive imaging techniques

    Cardiac CT and CMR (coronary and peripheral arteries) (central corelab)

    Time frame: Through study completion, up to 5 years

  5. Substudy on inflammation and biomarkers

    Comprehensive analysis of biomarkers. Coordinating center (HULP). Including leucocytes, HsCRP, IL6

    Time frame: Through study completion, up to 5 years

  6. Pharmacogenomic study

    Pharmacogenomic study. Coordinating center (HULP). Percent of responders to treatment according to the pharmacogenomic profile

    Time frame: Through study completion, up to 5 years

  7. Micro RNAs and Genetic studies

    Micro RNAs and Genetic studies. Coordinating center (HULP). Array of different micro-RNAs

    Time frame: Through study completion, up to 5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Alfonso F, de la Torre Hernandez JM, Ibanez B, Sabate M, Pan M, Gulati R, Saw J, Angiolillo DJ, Adlam D, Sanchez-Madrid F. Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with Spontaneous Coronary Artery Dissection) randomized clinical trial. Rev Esp Cardiol (Engl Ed). 2022 Jun;75(6):515-522. doi: 10.1016/j.rec.2021.08.003. Epub 2021 Sep 22. English, Spanish. PubMed 34561195 ↗

Individual participant data

Plan to share: Yes — To be decided by the steering committee upon formal official request by academic investigators

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After the primary endpoint is reported

Access criteria: To be discussed

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2021; primary completion for Dec 2024, 44 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2021
First posted
Apr 20, 2021
StartEst.
Apr 30, 2021
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2028
Last update
Apr 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04850417
Lead sponsor
Spanish Society of Cardiology
Collaborators
Instituto de Investigación Sanitaria Hospital Universitario de la Princesa, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Responsible party
Fernando Alfonso (Principal Investigator, Spanish Society of Cardiology) — Principal investigator
First posted
Apr 20, 2021
Start date
Apr 30, 2021 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 20, 2021

Study contacts

Fernando Alfonso, MD
Contact
falf@hotmail.com
34 680483165
Spanish Society of Cardiology Spanish Society of Cardiology
Contact
Spanish Society of Cardiology Spanish Society of Cardiology
study chair · Spanish Society of Cardiology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beta blockers · Aspirin · Clopidogrel

Start the discussion